MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., February 16, 2023 — MannKind Corporation (Nasdaq: MNKD) is set to release its 2022 fourth quarter and full year financial results on February 23, 2023, at 5:00 PM ET. The management will host a conference call to discuss these results and provide corporate updates. Presenters include CEO Michael Castagna and CFO Steven B. Binder. Interested parties can tune in via MannKind's website, with a replay available for 14 days. The company focuses on developing innovative therapeutic products for serious medical needs, particularly in endocrine and orphan lung diseases, utilizing dry-powder formulations and inhalation devices.
- None.
- None.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Thursday, February 23, 2023.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven B. Binder.
Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at mannkindcorp.com under Events & Presentations. A replay will be available on MannKind's website for 14 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.
MannKind Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
FAQ
When will MannKind release its fourth quarter and full year financial results?
Who will present the financial results conference call for MannKind?
How can I listen to MannKind's conference call?
Is there a replay available for MannKind's financial results call?
What is MannKind's focus as a company?
